Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04808648
Other study ID # SHC013-I-05
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date April 6, 2021
Est. completion date June 30, 2021

Study information

Verified date March 2021
Source Nanjing Sanhome Pharmaceutical, Co., Ltd.
Contact Huan Zhou, Ph D
Phone 13665527160
Email zhouhuan@bbmc.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I study to assess the drug-drug interaction of SH-1028 tablets and Itraconazole/Rifampicin tablets. The study also evaluates the pharmacokinetic and tolerability of SH-1028 tablets in healthy subjects. This study provides evidence for the designing of following clinical trial protocols.


Description:

A total of 40 evaluable healthy male subjects will be enrolled in this study.The subjects will be divided into two groups, A and B, with 20 people in each group. In the itraconazole study (Group A), patients received single-dose SH-1028 200 mg on Days 1 and 12 and itraconazole(200 mg twice daily) on Days 8-14 orally. In the rifampicin study (Group B), patients received SH-1028 200mg once daily on Days 1 and 14 and rifampicin 600 mg once daily on Days 8-16.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date June 30, 2021
Est. primary completion date June 10, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Healthy male volunteers between the age of 18 to 45 years old (including 18 and 45 years old) 2. Body weight between 50.0 and 80.0 kg, Body mass index between 19.0 and 26.0 kg/m2 (including 19.0 and 26.0 kg/m2); 3. Normal physical findings, clinical laboratory values, vital signs and 12-lead ECG, or any abnormality that is non-clinically significant; 4. Promise not to smoke, drink alcohol or drink caffeinated beverages during the trial; 5. Be able to communicate well with the researcher and be able to complete the trial in accordance with the program. 6. Male subjects of reproductive potential with partners will be instructed to,and must be willing to practice a highly effective method of birth control for the duration of the study and continuing 6 months after discontinuing treatment with the investigational product. Exclusion Criteria: 1. History of or current clinically significant cardio, pulmonary, endocrine, metabolism, renal, hepatic, gastrointestinal, dermatology, infection, hematology, neurological, mental disease or disorder. Or any other disease or physiological condition that may affect the results of the study; 2. Those who have undergone surgery within the first 3 months of the screening period, or who plan to undergo surgery during the study period, or who have previously undergone surgery that may affect drug absorption, distribution, metabolism, and excretion; 3. Subjects with dysphagia or have history of gastrointestinal disorders which affects study drug absorption; 4. Alcohol breath test results greater than 0.0mg/100mL. 5. Urine drug screening (morphine, methamphetamine, ketamine, dimethyldioxyamphetamine, tetrahydrocannabinol) positive; 6. Those who had received the vaccine within 28 days prior to screening, or who planned to receive the vaccine during the trial; 7. Positive test for HBs-Ag, HCV-Ab, HIV-Ab, or syphilis antibody; 8. Allergies, have allergies to drugs or foods; or have known allergies to the components of the investigated drug; 9. Those who smoked daily >5 sticks of cigarette, or the weekly alcohol consumption was higher than 14 units of alcohol (1 unit=10ml or 8g absolute alcohol. 25 ml 40% liquor, 330ml 5% beers, 175ml 12% grape wine are equal to 1.0, 1.5 and 2.0 units of alcohol respectively), or the history of drug abuse and drug abuseor 3 months prior to screening period; 10. Subjects with history of blood donation or massive blood loss (> 200 mL) within 3 months prior to screening; 11. Participated in other clinical trials within 3 months before screening; 12. Use of any drugs that alter liver enzyme activity within 28 days prior to screening; 13. Do not promise not to smoke, not drink alcoholic food or beverages, not consume xanthine-rich foods, not consume grapefruit, dragon fruit, mango, lime, carambola or other products within 24 hours before taking the study drug. Prepared foods or beverages, as well as chocolate, tea, coffee or cola and other special diets that affect the absorption, distribution, metabolism and excretion of drugs; 14. People who have used any medicine (including Chinese herbal medicine and health care products) within two weeks before taking the test drug; 15. History of syncope / needle syncope and intolerable intravenous indwelling needle; 16. Those who have special requirements for diet and cannot follow a unified diet; 17. hose who cannot complete this study because of other reasons, or any factors judged by investigator that the participants cannot meet.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SH-1028
tablet, oral, 200 mg once daily for day 1 and day 12
Itraconazole
capsule, oral, 200 mg twice daily for day 8 to day 14
Rifampicin
capsule, oral, 600 mg once daily for day 8 to day 16

Locations

Country Name City State
China the First Affiliated Hospital with Bengbu Medical College Bengbu Anhui

Sponsors (1)

Lead Sponsor Collaborator
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax Pharmacokinetics of SH-1028 by assessment of maximum plasma concentration Blood samples collected on Day 1 and Day 12 (arm 1)/Day 14 (arm 2) at pre-dose, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 96 hours post SH-1028 dose
Primary AUC(0-last) Pharmacokinetics of SH-1028 by assessment of area under the plasma concentration time curve from zero to last assessed timepoint Blood samples collected on Day 1 and Day 12 (arm 1)/Day 14 (arm 2) at pre-dose, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 96 hours post SH-1028 dose
Primary AUC(0-8) Pharmacokinetics of SH-1028 by assessment of area under the concentration time curve from time 0 to infinity Blood samples collected on Day 1 and Day 12 (arm 1)/Day 14 (arm 2) at pre-dose, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 96 hours post SH-1028 dose
Secondary Incidence of adverse events Safety and tolerability Up to 10 days after last dose
See also
  Status Clinical Trial Phase
Completed NCT05523687 - AME Study of [14C]-PC14586 in Healthy Male Participants Phase 1
Completed NCT02250976 - The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca Phase 1
Completed NCT01948011 - Racecadotril Suspension Linearity Study & Comparative Bioavailability Versus Granules Phase 1
Completed NCT04086719 - An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition. Phase 1
Completed NCT03686501 - D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562 Early Phase 1
Terminated NCT01965301 - First-time-in-man, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375 Phase 1
Completed NCT01005160 - Drug Interaction Between CKD-501 and Metformin Phase 1
Completed NCT04534582 - Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects Phase 1
Recruiting NCT06159101 - A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects Phase 1
Completed NCT01549743 - The Pharmacokinetic Interaction Between Celecoxib and Rebamipide Phase 1
Completed NCT03532854 - Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802 Phase 1
Recruiting NCT03530228 - A Phase 1 Study of Tegoprazan on Healthy Male Volunteers Phase 1
Completed NCT01356043 - CKD-828 Drug Interaction Study (S-amlodipine) Phase 1
Completed NCT04810533 - The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers Phase 1
Completed NCT03089112 - Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501 Phase 1
Completed NCT01939639 - The Influence of Oxytocin on the Processing of Social Contact Phase 1
Completed NCT01342055 - Pharmacokinetics and Safety Study of Apetrol ES in Healthy Male Volunteers Phase 1
Terminated NCT03863587 - Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult Subjects Phase 1
Completed NCT01606462 - Oxytocin and Social Cognition Phase 1
Completed NCT01382017 - Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study N/A